{
    "clinical_study": {
        "@rank": "36873", 
        "acronym": "BTSA", 
        "arm_group": {
            "arm_group_label": "Endoscopic lung volume reduction", 
            "arm_group_type": "Experimental", 
            "description": "After usual sedation, bronchoscope is introduce to the lung and palced in segmental wedge position then hot salineis instilled. Same procedure to others affected segments."
        }, 
        "brief_summary": {
            "textblock": "Aim: To  evaluate feasibility, safety and efficacy of relatively simple approach of\n      bronchoscopic lung volume reduction (LVR) technology, independent of collateral ventilation.\n\n      Description: Patients with severe upper lobes heterogeneous emphysema, undergo unilateral\n      bronchoscopic installation of saline thermal energy 50-55 \u00baC intending to induce an\n      inflammatory airway and parenchymal injury and consequently fibrotic response resulting in\n      LVR;"
        }, 
        "brief_title": "Bronchoscopic Thermal Saline Ablation (BTSA) of Emphysematous Lung. A New Emphysema Therapy", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Emphysema", 
        "condition_browse": {
            "mesh_term": [
                "Emphysema", 
                "Pulmonary Emphysema"
            ]
        }, 
        "detailed_description": {
            "textblock": "Inclusion criteria:\n\n        1. Age 40-75 unlimited sex. 20 subjects\n\n        2. chronic obstructive pulmonary disease (COPD),  GOLD 3-4 (global obstructive lung\n           disease).\n\n        3. CT scan of lung and included high resolution slices. Demonstrating emphysematous,\n           bullotic changes  in the upper lobes.\n\n        4. Pulmonary function tests results- total lung capacity(TLC)>110%, residual\n           volume(RV)>150%, diffusion of lung CO(DLCO)<80%,forced expiratory volume 1\n           second(FEV1):15-45%.\n\n        5. 6 minute walking distance (6MWD)> 140 meters.\n\n      Exclusion  criteria:\n\n        1. Active ischemic heart disease, significant arrhythmia. ejection fraction (EF) <40%.\n\n        2. COPD that cause carbon bioxide(CO2) retention above 50 mm Hg and / or oxygen saturation\n           at rest below 88%.\n\n        3. Pulmonary hypertension> 45 mmHg, according to the Echo Test.\n\n        4. . Cancer treatment with chemotherapy / radiation or expected life expectancy  of less\n           than two   years.5. Pregnancy.\n\n      Methods: . A. Patient preparation and sedation as in diagnostic bronchoscopy. Sedation will\n      be based on midzoln + demerol. The patients will be treated prior the treatment with\n      Inhalation with salbutamol ans ipratropium bromide. Flexible bronchoscope with outer\n      diameter 5 mm is introduced to the targated upper lobe, and placed in wedged position. This\n      is followed by installion of 0.9% natriu, chloride(NaCl) at a temperature of 55\u00baC exit\n      temperature 50\u00baC) in portions of 40 ml to 200 ml (in bronchoalveolar lavage up to 300 ml is\n      acceptable. The patient is placed in horizontal position, and continuous ECG blood pressure.\n      Oxygen saturation are monitored. This monitoring will be continue at least 2 hours after\n      treatment. A chest x-ray is followed and the patient remain in the department for overnight.\n\n      Tracking: Minimum of 6 months - Outpatient follow up include in addition to physical\n      examination extended pulmonary function test and after 3-6 months. low radiation chest CT."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age 40-75 unlimited sex. 20 subjects\n\n          2. COPD,  GOLD 3-4 (global obstructive lung disease).\n\n          3. CT scan of lung and included high resolution slices. Demonstrating emphysematous,\n             bullotic changes  in the upper lobes.\n\n          4. Pulmonary function  tests results- TLC> 110%, RV> 150%, DLCO <80%,FEV1: 15-45%.\n\n          5. 6 minute walking distance > 140 meters.\n\n             -\n\n        Exclusion Criteria:\n\n          1. Active ischemic heart disease, significant arrhythmia. Ejection fraction (EF) <40%.\n\n          2. Chronic lung disease that cause CO2 retention above 50 mm Hg and / or oxygen\n             saturation at rest below 88%.\n\n          3. Pulmonary hypertension> 45 mmHg, according to the Echo Test.\n\n          4. . Cancer treatment with chemotherapy / radiation or expected life expectancy  of less\n             than two   years.\n\n          5. Pregnancy -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01920321", 
            "org_study_id": "195/12"
        }, 
        "intervention": {
            "arm_group_label": "Endoscopic lung volume reduction", 
            "description": "Prior the procedure patients undergo - high resolution chest CT , extensive phisiological assessment.", 
            "intervention_name": "Endoscopic lung volume reduction", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "COPD", 
            "Bronchoscopic LVR", 
            "Emphysema", 
            "Hot injury"
        ], 
        "lastchanged_date": "August 8, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beer Yaakov", 
                    "country": "Israel", 
                    "zip": "70300"
                }, 
                "name": "Assaf Harofeh Medical Center"
            }, 
            "investigator": {
                "last_name": "David Stav, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "1", 
        "official_title": "Lung Volume Reduction in COPD Patients With an Inhomogeneous Severe Emphysema Located in the Upper Lobes, by Injecting Warm Saline Through the Bronchoscope Channel", 
        "overall_contact": {
            "email": "dstav@asaf.health.gov.il", 
            "last_name": "David Stav, MD", 
            "phone": "972- 89779024"
        }, 
        "overall_contact_backup": {
            "last_name": "Isaac Shpirer, MD", 
            "phone": "972- 89779024"
        }, 
        "overall_official": {
            "affiliation": "Assaf-Harofeh Medical Center", 
            "last_name": "david Stav, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Clinical - COPD assessment test (CAT ) + lung volumes + diffusion capaciry and 6MWD .", 
            "measure": "Pulmonary function improvemnt", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01920321"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Assaf-Harofeh Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Assaf-Harofeh Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}